title: Posterior reversible encephalopathy syndrome in patients with hematologic tumor confers worse outcome.
abstract: BACKGROUND
  This study aimed to evaluate the clinical features of posterior reversible encephalopathy syndrome (PRES) in children.
  
  
  METHODS
  The medical records of 31 patients from five medical centers who were diagnosed with PRES from 2001 to 2013 were retrospectively analyzed. In the 31 patients, 16 were males, and 15 females, with a median age of 7 years (3-12 years). Patients younger than 10 years accounted for 74.2% of the 31 patients.
  
  
  RESULTS
  Seizure, the most common clinical sign, occurred in 29 of the 31 patients. Visual disturbances were also observed in 20 patients. Cerebral imaging abnormalities were bilateral and predominant in the parietal and occipital white matter. In this series, three patients died in the acute phase of PRES. One patient had resolution of neurologic presentation within one week, but no apparent improvement in radiological abnormalities was observed at eight months. One patient showed gradual recovery of both neurologic presentation and radiological abnormalities during follow-up at eight months. One patient developed long-term cortical blindness. All of the PRES patients with hematologic tumor had a worse prognosis than those without hematologic tumor.
  
  
  CONCLUSIONS
  Seizure is a prevalent characteristic of children with PRES. Poor prognosis can be seen in PRES patients with hematologic tumor.
authors.affiliation: Department of Pediatrics, Chinese PLA General Hospital, Beijing, 100583, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Li
authors.forename: Ying
authors.initials: Y
authors.lastname: Liu
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
authors.forename: Xia
authors.initials: X
authors.lastname: Tan
authors.forename: Xiu-Yun
authors.initials: XY
authors.lastname: Ye
authors.forename: Ming-Sheng
authors.initials: MS
authors.lastname: Ma
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Huang
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Zou
mesh_terms: D000046:Academic Medical Centers; D000927:Anticonvulsants / Q000627:therapeutic use; D002423:Cause of Death; D002648:Child; D002675:Child, Preschool; D002681:China; D015331:Cohort Studies; D015897:Comorbidity; D018450:Disease Progression; D005260:Female; D019337:Hematologic Neoplasms / Q000175:diagnosis* / Q000453:epidemiology* / Q000628:therapy; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D054038:Posterior Leukoencephalopathy Syndrome / Q000175:diagnosis* / Q000453:epidemiology* / Q000628:therapy; D012016:Reference Values; D012189:Retrospective Studies; D018570:Risk Assessment; D012640:Seizures / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology; D012720:Severity of Illness Index; D016019:Survival Analysis
chemical_list: D000927:Anticonvulsants